Gladziwa U, Krishna D R, Klotz U, Ittel T H, Schunkert H, Glöckner W M, Mann H
Department of Internal Medicine III, Technical University of Aachen, Federal Republic of Germany.
Eur J Clin Pharmacol. 1988;35(4):427-30. doi: 10.1007/BF00561377.
The pharmacokinetics of ranitidine was investigated in 11 patients with acute or end stage renal failure during haemofiltration. Each patient received 50 mg ranitidine i.v. The mean distribution and elimination half lives were 0.13 and 2.57 h, respectively. The total body clearance (CL) and volume of distribution (Vz) were 298 ml.min-1 (5.19 ml.min-1.kg-1) and 1.08 l.kg-1, respectively. About 17.1% of the administered dose was removed by haemofiltration (in approximately 20 l filtrate). Five of the patients still had some urine output and they excreted 0.1 to 11.8% of the dose in urine in 24 h. The haemofiltration clearance was 66.9 ml.min-1 at a filtrate flow rate of 86 ml.min-1, corresponding to a mean sieving coefficient of 0.78 (n = 6). As plasma concentrations were still in an effective range after haemofiltration, dose supplementation is not recommended.
在11例急性或终末期肾衰竭且正在进行血液滤过的患者中研究了雷尼替丁的药代动力学。每位患者静脉注射50mg雷尼替丁。平均分布半衰期和消除半衰期分别为0.13小时和2.57小时。总体清除率(CL)和分布容积(Vz)分别为298ml.min-1(5.19ml.min-1.kg-1)和1.08l.kg-1。约17.1%的给药剂量通过血液滤过清除(在约20升滤液中)。5例患者仍有一些尿量,他们在24小时内尿中排泄了0.1%至11.8%的剂量。在滤液流速为86ml.min-1时,血液滤过清除率为66.9ml.min-1,平均筛系数为0.78(n = 6)。由于血液滤过后血浆浓度仍在有效范围内,不建议补充剂量。